290 patents
Page 5 of 15
Utility
Two-dimensional LC-MS/MS Systems
11 Aug 22
The present invention relates to a novel analytical method for detecting one or more analytes in a source sample by continuous flow 2D LC-MS/MS using a single LC system.
Wei-Lien Chuang, Felipe Gazos Lopes, Joshua Pacheco, Gerard Sanderink
Filed: 29 May 20
Utility
Tropomyosin-related kinase (TRK) inhibitors
9 Aug 22
Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease.
John L. Kane, Jr., Gloria Matthews, Markus Metz, Michael Kothe, Jinyu Liu, Andrew Scholte
Filed: 25 Sep 20
Utility
yor2axcd3j9tu 9b33rcfry9h96hovilmm6ikq0hv
4 Aug 22
Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI.
Luis Z. AVILA, Clark Q. PAN, Patrick FINN, John HARRAHY, Qun ZHOU, Yunxiang ZHU, Paul A. KONOWICZ, Duncan E. PATERSON, Andreas PEER, Joseph P. KUTZKO, Michael R. REARDON, James E. STEFANO, Xiaoyang ZHENG, Robert J. MILLER, Lauren YOUNG
Filed: 14 Feb 22
Utility
o6gp16i0crsyjpr74fv6c61zyix8gfg55quvbx rnij8
4 Aug 22
Provided herein are methods relating to the purification of a polypeptide comprising an Fc region (e.g., an antibody) via protein A chromatography; methods relating to the use of a wash solution comprising a benzoate salt and/or benzyl alcohol during protein A chromatography; and methods of adjusting a harvest using sodium benzoate prior to protein A chromatography.
Carl A. BEIGIE
Filed: 17 Dec 21
Utility
x476j16 z8qq6fk3g1bknegqbbbltzb2kj31sv2xt
19 Jul 22
Provided herein are methods of predicting the effect of a concentration of a sensitizer on cell viability in a production bioreactor, methods of improving cell viability in a production bioreactor, methods of predicting cell viability in a production bioreactor, and methods for culturing a cell in a production bioreactor.
Jonathan Wang, Neha Shah, Jason Walther, Jiuyi Lu, Timothy Johnson, Yukun Ren, Jean McLarty
Filed: 15 Mar 19
Utility
y37ezevl y5spx0vj361a5cjmnaxlml4idd
30 Jun 22
John L. Kane, JR., Nellwyn A. Hagan, Maria A. Fitzgerald
Filed: 11 Feb 22
Utility
2n94z57fne808kvi55mbpkv7waz
30 Jun 22
The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group.
Yunxiang ZHU, Seng H. CHENG, Canwen JIANG, Luis Z. AVILA
Filed: 10 Sep 21
Utility
gkujsihi6e6qnomk69binigh9l9pme
23 Jun 22
The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGFβ).
Brendan Lee, Kuber T. Sampath
Filed: 9 Dec 21
Utility
3mz1gq72ydiu42qlt5h6ickfs75uz9zrjdrdz3siyp4o1pqi swz0nmf9r69
16 Jun 22
Methods and kits for detecting antibodies (e.g., anti-drug antibodies).
Ryan Grabert, Susan Richards, Valerie Theobald, Yuanxin Xu, Jad Zoghbi
Filed: 23 Nov 21
Utility
dup1xbw4x0cfwmpb523ofdj23g3tbfovfm7xsmpj1vogh 7vewwi4w5
12 May 22
Provided herein are methods of culturing a mammalian cell in a liquid medium including poloxamer-188 at a concentration of 1.8 g/L or at a greater concentration than 1.8 g/L more or a liquid medium that includes a poloxamer-188 concentration that is selected based on one or more factors selected from the group of: pore size, pore type, gas flow rate, viable cell density in the medium, and markers related to cell stress.
Christopher Hwang, Timothy Johnson, Jason Walther, Cheng Cheng, Jonathan Wang, Neha Shah, Seul-A Bae
Filed: 11 Jan 22
Utility
rv6h2e0ajfwop1x7mv18ymy10tmybnf59ai3oimhp0 sypvp
10 May 22
A modified IgG antibody binds and neutralizes TGFβ1 selectively and with high affinity and avidity.
Huawei Qiu, Julie Bird
Filed: 3 Mar 16
Utility
kvmish2juvizzqvf1fccwd9
10 May 22
An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity.
Huawei Qiu, Clark Pan, Julie Bird
Filed: 30 Oct 19
Utility
3ezz2vmdoztjijzbhe9cn58l2392myw8u3ozmpwvip9mcdf2vpm38n
21 Apr 22
The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide.
Luis AVILA, Clark PAN, Huawei QIU, Qun ZHOU
Filed: 29 Mar 21
Utility
7x79phb2m sllugvrm0u1wvl84nyfkszcazgtcec39alnluqow5wn221em9
19 Apr 22
Provided herein are methods of culturing a mammalian cell in a liquid medium including poloxamer-188 at a concentration of 1.8 g/L or at a greater concentration than 1.8 g/L more or a liquid medium that includes a poloxamer-188 concentration that is selected based on one or more factors selected from the group of: pore size, pore type, gas flow rate, viable cell density in the medium, and markers related to cell stress.
Christopher Hwang, Timothy Johnson, Jason Walther, Cheng Cheng, Jonathan Wang, Neha Shah, Seul-A Bae
Filed: 21 Dec 15
Utility
j09fo2zqasp0xypnx4hu40fy5wrwyt574kmrd9ny6ngm1
14 Apr 22
Pharmaceutical formulations with a tropomyosin-related kinase inhibitor (“Trk inhibitor”) are disclosed.
Harvey Lieberman, Donglai Yang, C. Michael Philbrook, Michael Santos, Chris Ho
Filed: 20 Aug 21
Utility
zhm50oxc75t7rvzb4h8673qszaeucb79gq6t69kyp 6jh882
14 Apr 22
This disclosure relates to a method of treating a ciliopathy in a subject, the method comprising administering to the subject an effective amount of a quinuclidine compound.
Oxana IBRAGHIMOV-BESKROVNAYA, Nikolay O. BUKANOV, Hervé HUSSON, Sarah E. MORENO
Filed: 4 Feb 20
Utility
xbakm76v22uvgo5x0xt81pi97lrbrrvpxd5to7dau6jvz19m7p 2b1p9x
14 Apr 22
Provided herein are expression cassettes for expressing a transgene in a liver cell, wherein the transgene encodes a PAH polypeptide.
Sirkka R.M. KYOSTIO-MOORE
Filed: 30 Sep 21
Utility
epmbbwoivj3qtxku52 1rci
31 Mar 22
The present disclosure is related to improved methods for use of a humanized binding polypeptide specific for the alpha beta T cell receptor (αβ-TCR).
Gregor Blank, Rubert Handgretinger, Karin Schilbach, Gina Lacorcia, Daniel Snell, Andreas Menrad
Filed: 8 Sep 21
Utility
ruqzncss pt0m7dk4qsnx9zp0a3h5b157
31 Mar 22
The disclosure features methods that include obtaining a vibrational spectrum of a solution in a biological manufacturing system, analyzing the vibrational spectrum using a first chemometrics model to determine a value of a first quality attribute associated with the solution, analyzing the vibrational spectrum using a second chemometrics model to determine a value of a second quality attribute associated with the solution, and adjusting at least one parameter of a purification unit of the biological manufacturing system based on at least one of the values of the first and second quality attributes.
Dhanuka Pulasthi Wasalathanthri, Jagdish C. Tewari, Xuezhen Kang, Marina Hincapie, Shawn L. Barrett, Julie Susanne Pollock
Filed: 7 Dec 21
Utility
obb9hmpeavqo263qlvt8ukzethovkmarlcauycn 0k4wq
24 Mar 22
The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide.
Luis Z. Avila, Qun Zhou
Filed: 16 Aug 21